Leukapheresis is a medical procedure that involves the separation of white blood cells from the rest of the blood. It is primarily used for the treatment of blood cancers such as leukemia and lymphoma, as well as autoimmune disorders such as multiple sclerosis and rheumatoid arthritis. The leukapheresis market has been growing steadily in recent years and is expected to continue to do so throughout 2022-2030.
The global leukapheresis market is expected to grow at a compound annual growth rate (CAGR) of 8.5% during the forecast period of 2022-2030. The market size was valued at USD 65.5 million in 2022 and is expected to reach USD 125.8 million by 2030.
The increasing prevalence of blood cancers and autoimmune disorders, and the growing demand for personalized medicine. For instance, according to data from the Leukemia and Lymphoma Society, a projected 178,520 Americans received leukemia or lymphoma diagnosis in 2020, with new cases making up 9.9% of all diagnoses during that year. The demand for blood and blood components is on the rise globally. The requirement for leukocytes/WBCs increases with the rising adoption of leukapheresis in research and development activities are some of the key drivers of the leukapheresis market.
Some of the major players in the leukapheresis market include Haemonetics Corporation, Terumo BCT, Inc., Fresenius SE & Co. KGaA, Asahi Kasei Medical Co., Ltd., and Macopharma.
In October 2021, Haemonetics Corporation announced the launch of a new leukapheresis platform called NexSys PCS. The platform is designed to improve the efficiency and effectiveness of leukapheresis procedures, particularly in the treatment of blood cancers.
In June 2021, Terumo BCT, Inc. announced the acquisition of Gadaleta Medical Group, a leading provider of leukapheresis services in the United States. The acquisition is expected to strengthen Terumo BCT's position in the leukapheresis market.
Based on application, the leukapheresis market can be segmented into research and development, therapeutic applications, and others. The therapeutic applications segment is expected to grow at the highest CAGR during the forecast period, owing to the increasing prevalence of blood cancers and autoimmune disorders.
Based on product type, the leukapheresis market is segmented into leukapheresis devices and leukapheresis disposables. Centrifugal devices held the largest market share of the leukapheresis devices market in 2021 also it was the fastest growing segment in the forecast period due to increased installation of centrifugal apheresis devices in hospitals for therapeutic apheresis.
Based on End-user the leukapheresis market is segmented into pharmaceutical and biotechnology companies, academics and research institutes, blood component providers and blood centers, and hospitals and transfusion centers. The blood component providers and blood centers segment held the highest market share in 2021. However, hospitals and transfusion centers are expected to grow with the highest CAGR in the coming years.
Due to the growing elderly population as well as the rising frequency and incidence of leukemia in the region, North America is predicted to hold a significant market share in the leukapheresis industry. In 2022, the North American Association of Central Cancer Registries (NAACCR) predicts that 60,650 persons would receive a leukemia diagnosis. The Terry Fox Research Institute estimates that 21,700 persons in Canada received blood cancer diagnoses in 2019. People of all ages are affected by these diseases, and the kind of blood cancer has a significant impact on survival rates. Blood malignancies are believed to be the third biggest cause of cancer-related fatalities in Canada, taking the lives of 7,500 people.
The leukapheresis market is anticipated to develop at the greatest rate during the projected period in Asia-Pacific. The rising prevalence of leukemia in this area is one of the main drivers of the leukapheresis market's expansion. Also, the market is expanding due to government programs to support healthy lifestyles and technology improvements. The expansion of leukapheresis hospitals and blood centers in this region also contributes to the market's growth.
The leukapheresis market is expected to grow at a steady pace throughout 2022-2030, driven by the increasing prevalence of blood cancers and autoimmune disorders, the growing demand for personalized medicine, and the rising adoption of leukapheresis in research and development activities. Major players in the market include Haemonetics Corporation, Terumo BCT, Inc., Fresenius SE & Co. KGaA, Asahi Kasei Medical Co., Ltd., and Macopharma. Recent developments in the market include the launch of new leukapheresis platforms and the acquisition of leading providers of leukapheresis services. The market is segmented by product type, application, and End-user.